Blume Capital Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Blume Capital Management’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-350	Closed	-$18K	–	247
2015 Q4	$18K	Hold	350	–	–	0.01%	152
2015 Q3	$16K	Hold	350	–	–	0.01%	156
2015 Q2	$20K	Hold	350	–	–	0.02%	158
2015 Q1	$19K	Hold	350	–	–	0.01%	183
2014 Q4	$18K	Hold	350	–	–	0.01%	207
2014 Q3	$16K	Hold	350	–	–	0.01%	139
2014 Q2	$15K	Hold	350	–	–	0.01%	153
2014 Q1	$15K	Buy	+350	New	+$15K	0.01%	171

Other funds holding PBE

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TAM

Trillium Asset Management Boston, Massachusetts $3.01B AUM 19.96% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TCM

Traynor Capital Management Malvern, Pennsylvania $1.7B AUM 39.15% 1-Year Est. Return

HBT

Hills Bank & Trust North Liberty, Iowa $2.07B AUM 13.46% 1-Year Est. Return

CAS

Cue Advisory Services Phoenix, Arizona $167M AUM 18.62% 1-Year Est. Return

Blume Capital Management's PBE Position: Q1 2016 in Review

Blume Capital Management sold out of Invesco Biotechnology & Genome ETF (PBE) in Q1 2016, closing a stake of 350 shares — an estimated $18K sold.

Blume Capital Management first reported a position in PBE in Q1 2014 and held it in 8 quarters. The position peaked at $20K in Q2 2015. 71 funds tracked by Wall St. Rank hold PBE as of Q1 2016.

Blume Capital Management reported no remaining Invesco Biotechnology & Genome ETF position as of Q1 2016 after selling out during the quarter.
Blume Capital Management sold 350 Invesco Biotechnology & Genome ETF shares in Q1 2016, an estimated $18K.
Blume Capital Management first reported a position in Invesco Biotechnology & Genome ETF in Q1 2014 and held it in 8 quarters.
Blume Capital Management's Invesco Biotechnology & Genome ETF position peaked at $20K in Q2 2015.
71 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2016.

Based on Blume Capital Management's 13F filing for Q1 2016, filed 12 May 2016.